Advertisement Pfizer Canada launches ALK positive advanced or metastatic NSCLC therapy - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Pfizer Canada launches ALK positive advanced or metastatic NSCLC therapy

Pfizer Canada has announced the availability of Xalkori (crizotinib) for patients with anaplastic lymphoma kinase (ALK)-positive advanced or metastatic non-small cell lung cancer (NSCLC) in Canada.

A validated ALK assay should be used to assess ALK-positive advanced or metastatic NSCLC in patients.

The Xalkori oral monotherapy can be prescribed if the patients are ALK-positive and advanced (not amenable to curative therapy) or metastatic, according to the company.

Pfizer Canada oncology business unit general manager Richard Fajzel said, "Personalized medicine is a shift from a one size fits all intervention to an approach where physicians select treatments based on the genetic make-up of their patient’s disease."

In ALK-positive lung cancer, a normally dormant gene called ALK is fused with another gene, predominantly EML4, which results in a protein production that is believed to be a key driver of tumor development in cancers such as non-small cell lung cancer.